Cardiovascular Disease Screening

Sponsor
National Heart, Lung, and Blood Institute (NHLBI) (NIH)
Overall Status
Terminated
CT.gov ID
NCT00483951
Collaborator
(none)
1,325
2
153.2
662.5
4.3

Study Details

Study Description

Brief Summary

This study will evaluate volunteers 18 years of age and older to see if they qualify for one of NHLBI s research studies. Tests include the following:

  • General medical evaluation, which may include blood tests, chest x-ray, electrocardiogram (ECG) and echocardiogram (heart ultrasound).

  • Other tests as appropriate, such as magnetic resonance imaging (MRI), cardiac computed tomography (CT scan of the heart), nuclear stress test and echocardiography stress test.

  • X-ray contrast studies of the heart and blood vessels. (These may be excluded in patients with kidney risk factors.)

Condition or Disease Intervention/Treatment Phase
  • Device: Toshiba Aquilion ONE CT
  • Device: SWiemens MRI scanner

Detailed Description

This is a screening protocol. This protocol allows two functions: 1) the protocol allows physicians in the Suburban/NHLBI Cardiovascular Imaging program to evaluate patients referred to the program with clinically indicated studies and research studies. 2) It is also designed to determine if patients may be suitable candidates for one of our NHLBI research protocols.

Patients greater than or equal to 18 years of age referred for possible cardiovascular disease will be enrolled in the protocol for a period of one year. At one year, patients will either be: 1) transferred to one of our specific research MRI or CT protocols, 2) removed from the screening protocol and made inactive, or 3) re-enrolled on the screening protocol with the patient s consent.

Study Design

Study Type:
Observational
Actual Enrollment :
1325 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Suburban/NHLBI Cardiovascular Disease Screening Protocol
Actual Study Start Date :
Jan 28, 2008
Actual Primary Completion Date :
Nov 3, 2020
Actual Study Completion Date :
Nov 3, 2020

Arms and Interventions

Arm Intervention/Treatment
Patients with known or suspected cardiovascular disease

Patients referred to protocol with known or suspected cardiovascular disease for further evaluation.

Device: Toshiba Aquilion ONE CT
The Toshiba Aquilion ONE CT system has the ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy.

Device: SWiemens MRI scanner
Investigational or research MRI coils may be used in the protocol. The coils are noninvasive devices external to the body. The coils act as antennae to receive small radiofrequency signals out of the body. Coils of the type we use are used daily in clinical MRI practice.

Outcome Measures

Primary Outcome Measures

  1. Complete characterization of patients for screening purpose onto a research protocol. [Ongoing]

    Complete characterization of patients for the purpose of deciding whether they are eligible for research protocols run by the Cardiovascular Branch.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
  • ELIGIBILITY CRITERIA:

No one will be excluded from this study based on race, gender, or ethnicity.

A. General Inclusion Criteria:
  • Age greater than or equal to 18

  • Capable of giving informed consent.

B. General Exclusion Criteria:
  • Pregnant women (uncertain patients will have urine or blood testing).

  • Decompensated heart failure (unable to lie flat in bed).

Test Specific Exclusion Criteria:
A. CT Exclusion Criteria (excludes contrast enhanced CT scan only):
  • Allergy to iodinated contrast agent excludes contrast enhanced CT research studies.

  • Multiple myeloma.

  • Patients with severe kidney disease (eGFR less than 30 mL/min/1.73 m(2).

B. Beta Antagonist Exclusions (excluded the use of beta blocker only):
  • Asthma or severe chronic lung disease/emphysema with regular use of inhaler.

  • Decompensated heart failure.

C. MRI Exclusion Criteria (excludes MRI scan only):
  • Cardiac pacemaker or implantable defibrillator.

  • Cerebral aneurysm clip.

  • Neural stimulator (e.g. TENS-Unit).

  • Any type of ear implant.

  • Metal in eye (e.g. from machining).

  • Any implanted device (e.g. insulin pump, drug infusion device).

D. Exclusions from MRI contrast agents:
  • Lactating women unless they are willing to discard breast milk for 24 hours.

  • Severe kidney disease (less than 30 mL/min/1.73 m(2).

E. Vasodilator Exclusions (excludes some vasodilator stress testing):
  • Asthma or chronic obstructive pulmonary disease (emphysema) actively treated with bronchodilators or leukotriene receptor antagonists (albuterol, seravent, atrovent, montelukast singulair, zafirlukast Accolate. These conditions only exclude adenosine and dipyridamole.

  • Second degree (Type II) and third degree atrioventricular heart block.

F. Exclusions from Dobutamine stress MRI only:
  • Severe problems with heart rhythms.

  • Severe high blood pressure.

  1. Exclusion criteria for atropine (given during dobutamine stress echocardiography when target heart rate not achievable with dobutamine alone).
  • Narrow angle glaucoma.

  • Known or suspected severe bladder outlet obstruction due to prostatic hypertrophy.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Suburban Hospital Bethesda Maryland United States 20814
2 National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland United States 20892

Sponsors and Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

Investigators

  • Principal Investigator: Andrew E Arai, M.D., National Heart, Lung, and Blood Institute (NHLBI)

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00483951
Other Study ID Numbers:
  • 070157
  • 07-H-0157
First Posted:
Jun 8, 2007
Last Update Posted:
Jul 29, 2021
Last Verified:
Nov 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Keywords provided by National Heart, Lung, and Blood Institute (NHLBI)
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 29, 2021